Markus Peters

Consultant, former Chief Commercial Officer

Back to Speakers

Markus Peters, PhD MSc is an experienced global biopharmaceutical executive with a 23 year track record of developing and commercializing innovative, high value orphan and specialty pharmaceuticals for patients with high unmet medical need.
At present, Markus is an executive level strategic consultant for biopharmaceutical companies. Before that, Markus was Chief Commercial Officer with Agilis Biotherapeutics, a biopharmaceutical company advancing gene therapies for patients with rare diseases of the Central Nervous System. In this role, he had responsibility for Market Access, Medical Affairs, Marketing, Diagnostic Field Services, Sales and Business Development, including the preparation for the launch of AGILD AADC, the first gene therapy for ultra rare AADC deficiency. Agilis was acquired by PTC Therapeutics in August 2018. Before that, he was Vice President Global Marketing with Synageva BioPharma, and Senior Director Global Marketing with Alexion Pharmaceuticals, with responsibility for the launches of two ultra orphan franchises (Kanuma for LAL deficiency and Soliris for atypical HUS). Prior to that, Markus led the global launches of the ENBREL franchises for Wyeth/Pfizer (>$5B sales). He also worked 5 years in Japan with Boehringer Ingelheim in commercial roles of increasing responsibility.
Markus is a leader in sizing & building of global biotech organizations with comprehensive operational responsibility (Agilis, Synageva, Alexion), hiring and leading key organizational functions located across the globe. He has extensive operational experience on 3 continents: North America (US), Europe (Germany and UK), and Asia (5 years in Japan; China).
As commercial lead, he supported corporate deals, including the $8.4B acquisition of Synageva by Alexion, at the time 4th largest deal in the industry, and the acquisition of Agilis by PTC Therapeutics, a deal valued at ~$1B ($200M upfront with ~$800M future milestone payments).
Markus has experience across a broad range of therapeutic areas, leading pipeline commercialization for AAV gene therapy in neurology (Agilis); therapies for inborn errors of metabolism, hepatology (Synageva); transplant, nephrology and immunology (Alexion); endocrinology (Merck); and oncology (Wyeth/Pfizer).
Markus holds a PhD in Biochemistry and a MSc in Chemistry (Dipl. Chem.) from Heinrich Heine University Düsseldorf/Germany.